semaglutide cardiac protection The Cardioprotective Effects of Exceed Those of Dietary Weight Loss in Mice With HFpEF FDA Approves GLP-1 Pill for

Appeal strategy notes: Cite FDA approvals explicitly (December 2024 OSA indication) For OSA: include sleep study results and CPAP trial documentation For obesity: emphasize BMI history, comorbidities, and prior intervention Request peer-to-peer review before formal appeal Track all deadlines Decision framework If you have UnitedHealthcare commercial coverage and BMI 30+: Submit standard PA with comorbidity documentation

Fertility changes: Weight loss can sometimes improve ovulation, which might make pregnancy more likely

You might NOT be able to take GLP-1 if you have a history of pancreatitis, kidney disease/kidney insufficiency, Stomach problems, diabetes (must be approved from endocrinologist) or gall bladder disease

Long-term maintenance therapy is usually necessary to sustain weight loss benefits